Can-Fite’s Namodenoson Shows Promising Survival Signals in Advanced Pancreatic Cancer Phase 2a Study

Can-Fite’s Namodenoson met safety endpoint and showed encouraging survival signals in Phase 2a pancreatic cancer study, including median OS >5 months in third-line patients and one survivor over 18 months.